MarketPulse

cannabis legalization

3 articles
The Motley FoolThe Motley Fool··David Jagielski, Cpa

Tilray's U.S. Pot Dream Faces Long Road Despite Rescheduling Victory

Cannabis rescheduling offers hope but legalization remains years away. Tilray investors shouldn't bet on near-term U.S. market entry.
TLRYstock performanceinvestment risk
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Tilray's Revenue Gains Mask Deeper Problems: Why Skeptics Remain Unconvinced

Tilray posts record $217.5M quarterly revenue and narrows losses, but persistent negative cash flow and competitive headwinds keep investors wary.
TLRYrevenue growthcannabis stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

From $300 to Pennies: Can Canopy Growth Survive Its Existential Crisis?

Canopy Growth stock has crashed 99% from $300 to under $2, posting weak financials and facing structural industry headwinds despite U.S. cannabis reclassification.
CGCstock declinefree cash flow